Compositions and methods for treating age-related diabetes and related disorders
AssigneeThe Salk Institute for Biological Studies
InventorsSagar P. Bapat, Ye Zheng, Ronald Evans, Michael Downes, Annette R. Atkins, Ruth T. Yu
Life of this patent
Estimating the term…
Abstract
The invention features compositions and methods treating or preventing for age-related insulin resistance, type 2 diabetes and related disorders. The method involves depleting fTreg cells with an anti-ST2 antibody to decrease age-related fTreg accumulation and restore insulin sensitivity, thereby treating age-related insulin resistance, type 2 diabetes and related disorders.
Claims15
A method of enhancing insulin sensitivity or reducing insulin resistance in a subject in need thereof, the method comprising administering to the subject an anti-ST2 antibody or an antigen binding fragment thereof, thereby decreasing the number of adipose-resident regulatory T cells in the subject and enhancing insulin sensitivity or reducing insulin resistance in the subject wherein the subject is insulin insensitive, insulin resistant, or has an increased level of fat-resident regulatory T cells (fTregs) relative to the levels in a normal control.
A method for treating age-related insulin resistance, type 2 diabetes, metabolic dysregulation and related disorders in a subject in need thereof, the method comprising administering to the subject an anti-ST2 antibody or antigen binding fragment thereof, thereby treating age-related insulin resistance, type 2 diabetes, metabolic dysregulation and related disorders in the subject.
A method of enhancing insulin sensitivity or reducing insulin resistance in a subject at risk of insulin insensitivity or resistance, the method comprising:
- administering to a subject who has or has been predetermined to have one or both of an increased level of fat-resident regulatory T cells (fTregs) or increased amounts of visceral or subcutaneous adipose tissue relative to the levels or amounts in a normal control, an anti-ST2 antibody or an antigen binding fragment thereof, thereby decreasing the number of fTregs in the subject and enhancing insulin sensitivity or reducing insulin resistance in the subject.
Dependencies are inferred from the claim text.